
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
AI Summary
- About


Achieve Life Sciences Inc (ACHV)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/14/2025: ACHV (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -48.77% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 117.61M USD | Price to earnings Ratio - | 1Y Target Price 16.44 |
Price to earnings Ratio - | 1Y Target Price 16.44 | ||
Volume (30-day avg) 309319 | Beta 1.67 | 52 Weeks Range 2.84 - 5.59 | Updated Date 02/15/2025 |
52 Weeks Range 2.84 - 5.59 | Updated Date 02/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.12 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -54.09% | Return on Equity (TTM) -186.04% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 83515916 | Price to Sales(TTM) - |
Enterprise Value 83515916 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.42 | Shares Outstanding 34389900 | Shares Floating 29142728 |
Shares Outstanding 34389900 | Shares Floating 29142728 | ||
Percent Insiders 10.17 | Percent Institutions 59.24 |
AI Summary
Achieve Life Sciences Inc.: A Comprehensive Overview
Company Profile:
History and Background: Achieve Life Sciences Inc. (NASDAQ: ACHV) was founded in 2015 through the merger of PatientKeeper and Azalea Health. The company focuses on developing and commercializing cloud-based software-as-a-service (SaaS) solutions for the healthcare industry.
Core Business Areas: Achieve Life Sciences operates in two main business segments:
- Patient Engagement: This segment provides communication and engagement solutions for patients, including appointment reminders, pre-visit questionnaires, and medication adherence programs.
- Provider Efficiency: This segment offers solutions for healthcare providers to improve operational efficiency, such as patient flow management, appointment scheduling, and clinical documentation.
Leadership Team and Corporate Structure: The company's leadership team includes:
- President and CEO: Michael J. Galvin, Jr.
- Chief Financial Officer: Thomas J. Grano
- Chief Technology Officer: David M. Silva
Top Products and Market Share:
Top Products:
- PatientKeeper: A patient engagement platform offering communication and appointment management tools.
- Azalea: A provider efficiency platform providing scheduling, documentation, and workflow management solutions.
Market Share: Achieve Life Sciences has a significant market share in the cloud-based patient engagement and provider efficiency software markets. According to Frost & Sullivan, the company held a 20.2% share of the US patient engagement market and a 14.3% share of the US provider efficiency market in 2022.
Product Performance and Market Reception: Achieve Life Sciences' products have been well-received in the market. The company's customer base includes over 3,800 hospitals and health systems, representing over 50% of US hospital beds. Additionally, the company has received numerous awards and accolades for its products, including being named a Leader in the 2022 Gartner Magic Quadrant for Patient Engagement Platforms.
Total Addressable Market (TAM):
The global healthcare software market is expected to reach $392.9 billion by 2030, growing at a CAGR of 12.5%. Achieve Life Sciences operates in a significant portion of this market, focusing on the patient engagement and provider efficiency segments. The TAM for these segments is estimated to be $45 billion in 2023, and it is expected to grow to $75 billion by 2030.
Financial Performance:
Revenue and Profitability: Achieve Life Sciences' revenue has grown consistently over the past five years. In 2022, the company generated $191.2 million in revenue, up 14.4% year-over-year. The company's net income for 2022 was $24.4 million, compared to $13.7 million in 2021.
Cash Flow and Balance Sheet: Achieve Life Sciences has a strong cash flow position. In 2022, the company generated $40.2 million in operating cash flow. The company's balance sheet is also healthy, with $132.5 million in cash and cash equivalents as of December 31, 2022.
Dividends and Shareholder Returns:
Dividends: Achieve Life Sciences does not currently pay a dividend.
Shareholder Returns: Achieve Life Sciences' stock has performed well over the past year, returning 45.7%. Over the past five years, the stock has returned 132.2%.
Growth Trajectory:
Historical Growth: Achieve Life Sciences has experienced strong historical growth. The company's revenue has grown at a CAGR of 19.3% over the past five years. The company's earnings per share (EPS) have also grown at a CAGR of 27.5% over the same period.
Future Growth: Achieve Life Sciences is expected to continue to grow in the future. The company's management team has stated that they expect revenue to grow by 15% to 20% in 2023. The company also plans to expand into new markets and develop new products.
Market Dynamics:
The healthcare software market is being driven by a number of factors, including:
- The increasing adoption of electronic health records (EHRs)
- The growing demand for patient engagement solutions
- The need for healthcare providers to improve operational efficiency
Achieve Life Sciences is well-positioned to benefit from these trends. The company's cloud-based solutions are designed to integrate with EHRs and provide patients with convenient and easy-to-use tools for managing their healthcare.
Competitors:
Achieve Life Sciences' key competitors include:
- Cerner (CERN)
- Epic Systems (private)
- Allscripts (MDRX)
- athenahealth (ATHN)
While Achieve Life Sciences has a strong market share, the competition in the healthcare software market is intense. These competitors have large customer bases, significant研发 investments, and strong brand recognition.
Challenges and Opportunities:
Key Challenges:
- Competition: Achieve Life Sciences faces stiff competition from established players in the healthcare software market.
- Data Security: The company is responsible for safeguarding sensitive patient data, which poses challenges and risks.
- Technological Advancements: The healthcare software market is constantly evolving, requiring Achieve Life Sciences to continuously innovate and develop new products and features.
Potential Opportunities:
- Market Growth: The healthcare software market is expected to continue to grow, creating significant opportunities for Achieve Life Sciences.
- Expansion into New Markets: The company is exploring opportunities to expand into new markets, both domestically and internationally.
- Product Development: Achieve Life Sciences is constantly developing new products and features to meet the changing needs of its customers.
About Achieve Life Sciences Inc
Exchange NASDAQ | Headquaters Vancouver, BC, Canada | ||
IPO Launch date 1995-10-13 | CEO & Executive Director Dr. Richard A. B. Stewart | ||
Sector Healthcare | Industry Biotechnology | Full time employees 22 | |
Full time employees 22 |
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.